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Purpose of the study
To describe the effects of switching from a tenofovir-based
regimen to entecavir for hepatitis B (HBV) suppression in
HIV/HBV co-infected patients with previously undetecta-
ble HBV DNA.
Methods
HBV/HIV co-infected patients who required discontinua-
tion of tenofovir-based antiretroviral therapy due to neph-
rotoxicity and who were switched to entecavir for ongoing
HBV suppression were assessed. Patients were followed
prospectively with monthly monitoring of liver enzymes
and HBV DNA.
Summary of results
Six patients switched from tenofovir to entecavir in 2007.
All patients were male with a median age of 49 yrs (IQR
46–58 yrs) and a median CD4 count of 500 cells/mm3
(IQR 253–658 cells/mm3). All patients were hepatitis Be
antigen positive, and had undetectable HBV viral loads
while on tenofovir therapy prior to initiation of entecavir.
5/6 patients had prior HBV DNA samples available for
genotypic testing; 100% revealed evidence of baseline
lamivudine resistance (presence of L180 M + M204 V) but
no evidence of entecavir-associated resistance mutations.
Patients were treated with entecavir 1 mg daily or renally-
adjusted equivalent. Lamivudine was maintained within
the antiretroviral regimen of 5/6 patients. All patients
experienced HBV rebound on entecavir. Median time to
HBV virologic rebound was 2 months (range 1–11
months), and the median HBV DNA viral load at rebound
was 226,012 copies/mL (IQR 6,771–492,237 copies/mL).
Only one patient experienced a rise in ALT (to 143 IU/mL)
at the time of initial HBV rebound. All patients main-
tained HIV virologic suppression during the substitution
period and at the time of HBV rebound.
Conclusion
Entecavir has been shown to successfully suppress lamivu-
dine-refractory HBV in mono-infected patients. Entecavir
may be less potent than tenofovir at maintaining HBV
suppression in HBV/HIV co-infected patients. These
patients should be monitored closely for HBV rebound in
the setting of therapeutic substitution of entecavir for ten-
ofovir.
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